Conference Coverage
Conference Coverage
Drug efficacy in phase 2 RA trials often missing in phase 3
MADRID – Meta-analysis of 44 pairs of phase 2 and phase 3 RA trials showed that phase 2 results often overestimate efficacy.
Conference Coverage
Tildrakizumab shows positive effects in active psoriatic arthritis
MADRID – Already approved as a treatment for chronic plaque psoriasis, tildrakizumab (Ilumya) may also be beneficial in psoriatic arthritis,...
Conference Coverage
Repeated ANA testing after negative result of little diagnostic value
MADRID – In a retrospective analysis, 79% of repeated antinuclear antibody tests for ANA-associated rheumatologic conditions remained the same....
Conference Coverage
Ixekizumab boosts quality of life in genital psoriasis
MILAN – After 1 year of treatment, about half of patients said their psoriasis had no impact on quality of life.
Video
RNase drug shows promise for Sjögren’s fatigue
MADRID – RSLV-132 improved fatigue symptoms in patients with primary Sjögren’s syndrome in the phase 2, randomized, proof-of-concept RESOLVE study...
Conference Coverage
Flu vaccine succeeds in TNF inhibitor users
MADRID – The number needed to vaccinate to prevent one case of influenza among patients taking adalimumab is much lower than it is for healthy...
Conference Coverage
Some burnout factors are within a physician’s control
SAN DIEGO – Even in the face of daunting systemic factors, physicians can practice some important steps toward self-care.
Conference Coverage
Unacceptable pain despite inflammation control commonly occurs in PsA patients
MADRID – The percentage with unacceptable pain despite inflammation control was twice as high for nonresponders versus responders to anti-TNF...
Conference Coverage
Claims data suggest endometriosis ups risk of chronic opioid use
Women with endometriosis had a nearly 300% higher rate of chronic opioid use, compared with those without endometriosis, according to an analysis...
Guidelines
EULAR keeps csDMARDs as top PsA drugs
EULAR’s revised psoriatic arthritis recommendations retain methotrexate and other csDMARDS as first-line treatment over TNF inhibitors.
Conference Coverage
Quality standards aim to improve worldwide spondyloarthritis care
MADRID – The Assessment of SpondyloArthritis international Society (ASAS) has developed nine new quality standards to improve the management of...